StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
4
Publishing Date
2022 - 03 - 31
1
2022 - 02 - 02
1
2022 - 01 - 20
1
2021 - 11 - 03
1
Sector
Health technology
4
Tags
Alliances
2
America
1
Artificial intelligence
1
Asco
4
Award
1
Biocanada
21
Biomarkers
2
Biotech
85
Biotech-beach
2
Breast
6
Breast cancer
9
Cancer
41
Cancer drug
1
Cel
1
Ces
1
Chinese
3
Clinical-trials-phase-ii
4
Companies
1
Conference
19
Designation
1
Drug
1
Earnings
4
Ema
2
Enroll
1
Events
8
Fast track designation
2
Fda
5
Financial
12
Financial results
7
For
1
Gastrointestinal
4
Glioblastoma
1
Growth
3
Immunotherapy
2
Iot
31
Meeting
11
N/a
48
Negative
2
Pancreas
2
Pancreatic
14
People
2
Phase 1
6
Phase 2
2
Phase 2b
2
Positive
8
Potential
2
Pre-clinical
5
Preclinical
5
Presentation
9
Research
7
Response
3
Results
26
Study
4
Success
2
Symposium
5
Test
3
Therapy
6
Treatment
9
Trial
14
Year
5
Entities
Oncolytics biotech inc.
4
Symbols
AADI
1
ABBV
3
ABT
3
ALKS
1
ALLK
2
ANAB
1
AZN
3
AZNCF
2
BAX
1
BDX
1
BGNE
2
BHC
5
BPMC
2
BRKR
1
BSX
7
CALA
1
CNMD
5
COGT
3
CRDF
2
DCPH
6
DHR
2
EIGR
1
EVOK
2
EXEL
1
FNCTF
1
FWBI
1
GH
3
GLAXF
3
GSK
3
HCM
1
HLN
1
HLNCF
1
HOTH
1
IKT
1
IMAB
1
IMUX
1
IRWD
1
ISRG
1
JNJ
6
LLY
1
LPTX
2
MACK
2
MDT
8
MOTS
2
NTRA
2
NVO
2
NVS
3
NVSEF
3
OMGA
3
ONCY
4
PALI
2
RNXT
3
SNY
4
SNYNF
3
STE
2
SYK
4
TAK
2
THRX
2
TPTX
2
ZYME
3
Exchanges
Nasdaq
4
Crawled Date
2022 - 03 - 31
1
2022 - 02 - 02
1
2022 - 01 - 20
1
2021 - 11 - 03
1
Crawled Time
12:00
2
13:00
1
14:00
1
Source
www.biospace.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Gastrointestinal
symbols :
ONCY
save search
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Published:
2022-03-31
(Crawled : 12:00)
- biospace.com/
ONCY
|
$1.045
-3.24%
-3.35%
180K
|
Health Technology
|
-30.82%
|
O:
3.14%
H:
0.0%
C:
-3.66%
biotech
gastrointestinal
trial
positive
cancer
phase 1
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Published:
2022-02-02
(Crawled : 13:00)
- biospace.com/
ONCY
|
$1.045
-3.24%
-3.35%
180K
|
Health Technology
|
-42.11%
|
O:
0.53%
H:
0.0%
C:
0.0%
biotech
gastrointestinal
trial
phase 1
test
positive
cancer
iot
pancreatic
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Published:
2022-01-20
(Crawled : 14:00)
- biospace.com/
ONCY
|
$1.045
-3.24%
-3.35%
180K
|
Health Technology
|
-39.89%
|
O:
4.37%
H:
6.81%
C:
3.14%
biotech
america
symposium
gastrointestinal
trial
phase 1
test
cancer
iot
enroll
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
Published:
2021-11-03
(Crawled : 12:00)
- biospace.com/
ONCY
|
$1.045
-3.24%
-3.35%
180K
|
Health Technology
|
-48.6%
|
O:
1.4%
H:
0.49%
C:
-1.84%
phase 1
test
cancer
biotech
gastrointestinal
iot
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
News
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.